echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > VAXNEUVANCE (pneumococcal 15-valent conjugate vaccine) may be used in Europe for people 18 years and older

    VAXNEUVANCE (pneumococcal 15-valent conjugate vaccine) may be used in Europe for people 18 years and older

    • Last Update: 2021-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Merck announced today that the European Medicines Management Agency Committee medicines for human use (CHMP) has recommended approval VAXNEUVANCE ™ (Pneumococcal 15 valent conjugate vaccine) for active immunization to prevent 18-year-old and Streptococcus pneumoniae caused more than individual invasive Disease and pneumonia
    .

    Management Immunization Prevention

    The CHMP proposal will now be reviewed by the European Commission for marketing authorization in the EU, and a final decision is expected to be made by the end of the year
    .

    CHMP’s opinion is based on data from seven randomized, double-blind clinical studies that evaluated 7,438 individuals from various adult populations and clinical situations
    .


    In July 2021, VAXNEUVANCE was approved by the U.


    FDA

    Pneumococcal disease (an infection caused by Streptococcus pneumoniae ) is circulating globally
    .


    Highly invasive strains or serotypes may put more people at risk of invasive pneumococcal diseases such as bacteremia (blood infection)


    Infect

    VAXNEUVANCE is Merck's 15-valent pneumococcal conjugate vaccine, which is composed of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 32F and 32F.
    Purified capsular polysaccharide composition, coupled with CRM197 carrier protein
    .

    VAXNEUVANCE is Merck's 15-valent pneumococcal conjugate vaccine, which is composed of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 32F and 32F.
    Purified capsular polysaccharide composition, coupled with CRM197 carrier protein
    .


    VAXNEUVANCE is Merck's 15-valent pneumococcal conjugate vaccine, which is composed of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 32F and 32F.


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.